Shire links with Italian foundation for research on rare diseases

Shire (LSE: SHP) has announced a long-term, broad based, multi-indication research collaboration in rare diseases with Fondazione Telethon, a major Italian biomedical charitable foundation, for research carried out at the Telethon Institute of Genetics and Medicine (TIGEM).

This alliance will facilitate research on 13 undisclosed rare disease indications and has the potential to add multiple, novel therapeutic candidates into Shire’s early stage pipeline. The partnership underscores Shire’s long-term commitment to bring innovative therapies to patients with rare diseases worldwide.

The collaboration brings together Shire’s established capabilities in developing and distributing effective, life-altering therapies for patients with rare diseases and TIGEM’s world renowned research expertise in gene therapy and other novel therapeutics.